Nippon India Pharma Fund
Nippon India Mutual Fund · Best Sectoral & Thematic Mutual Funds
This is the Regular plan of Nippon India Pharma Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.
Performance
Scorecard
★★★★★5/5 vs 145 of 257 Sectoral/ Thematic peers- Performance 60%
- Risk 15%
- Cost 10%
- Downside 15%
How this is computed
Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). 145 of the 257 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.
3Y CAGR +16.77% · ranks 36 of 145 Sectoral/ Thematic funds
Volatility 13.1% vs 15.8% category avg
1.9% expense vs 2.5% category avg
96% of rolling 3Y windows were positive
Strengths & concerns
Generated from this fund's own numbers against its sub-category — each point names the figure behind it.
Strengths
- Ahead of the Sectoral/ Thematic average on 1M/3M/1Y — 1Y by 8.64pp
- 3-year return (+16.77%) beats the Sectoral/ Thematic average (+13.01%)
- 5-year return (+14.20%) beats the Sectoral/ Thematic average (+11.73%)
- Ranks #42 of 238 on 1-year return in its Sectoral/ Thematic cohort
- Stronger risk-adjusted returns — Sharpe 0.78 vs 0.40 Sectoral/ Thematic average
Concerns
No significant concerns identified.
Key Metrics
Scheme Info
DefinitionsPeriod returns (<1Y, absolute — not annualized)
DefinitionsAnnualized returns (≥1Y — CAGR)
DefinitionsAdvanced metrics — risk and benchmark ratios
Fund vs category average (Sectoral/ Thematic)
| Period | Fund | Category avg. | Diff |
|---|---|---|---|
| 1M abs | +10.38% | +6.05% | +4.33% |
| 3M abs | +2.77% | +0.25% | +2.52% |
| 6M abs | +6.86% | +7.31% | -0.45% |
| 1Y CAGR | +13.07% | +4.43% | +8.64% |
| 3Y CAGR | +16.77% | +13.01% | +3.76% |
| 5Y CAGR | +14.20% | +11.73% | +2.47% |
Category average across peers in Sectoral/ Thematic (up to 257 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).
Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.
Category rank
Vs 257 peers in Sectoral/ Thematic
Backtest this fund
What a SIP or one-time investment would have grown to over this fund’s real NAV history.
60 monthly installments of ₹10,000 into Nippon India Pharma Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.
Calendar-year returns
What the fund actually returned in each year, not the smoothed average.
| Year | Fund | Nifty Healthcare TRI | Diff | |
|---|---|---|---|---|
| 2026part | +15.07% | +19.00% | -3.93% | |
| 2025 | -3.34% | -1.53% | -1.81% | |
| 2024 | +34.04% | +41.34% | -7.30% | |
| 2023 | +39.15% | +33.89% | +5.26% | |
| 2022 | -9.90% | -10.17% | +0.27% | |
| 2021 | +23.93% | +19.01% | +4.92% | |
| 2020 | +66.44% | — | — | |
| 2019 | +1.68% | — | — | |
| 2018 | +3.64% | — | — | |
| 2017 | +7.61% | — | — |
January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.
Taxation
Taxed as equityThis is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.
Flat, on the whole gain
On gains above ₹1.25 L per financial year
Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.
Asset allocation
As on 31 Oct 2026 · AMC disclosure- Equity99.62%
- Cash & Equivalents0.38%
Fund size over time
Quarterly average AUM · AMFIAt or near its largest, ₹9,272Cr in July - September 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.
Net flow is an estimate: AMFI publishes a quarterly average AUM, not a closing balance, and it covers every plan and option of this scheme together, so it is a read on direction and rough size rather than a cash-flow statement.
AMC Profile
Nippon India Mutual Fund is managed by Nippon Life India Asset Management, which took control of the former Reliance Mutual Fund in 2019 when Nippon Life of Japan bought out the Reliance Capital stake. It is among India's largest fund houses by assets and is best known for its small- and mid-cap franchise.
Fund Managers
SBSailesh Raj BhanManaging since 01 Jun 2004
CIO – Equity Investments
MBA(Finance) CFA (ICFAI)
Over 29 years experience in Equity Securities research and analysis February 2014 to till date Deputy CIO - Equity Investments, NAM India, – managing various Schemes of NIMF. May 2010 to January 2014 Sr. Fund Manager - Investment Equity Oct 2006 to April 2009 Fund Manager -Equity Nov 2003 – Sept 2006 NAM India - Senior Analyst 2001-2003 Emkay Share & Stock Broker Pvt. Ltd Head – Research 1996-2001 Shah & Sequeira Invst. Pvt. Ltd Analyst - Equity research 1995-1996 ICFAI- Securities Research Center Analyst - Equity Research
Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Benchmark and dealing terms from it and this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.
Explore from here
Nippon India in the news
Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.
IIFL Finance shares drop over 3 pc after Fairfax pared over 13 pc stake
bfsi.economictimes.indiatimes.com · 15h ago
IIFL Finance Shares Tumble Over 3% After ₹3,488 Crore Mega Deal, Fairfax Almost Bids Goodbye With Just 0.4%
Free Press Journal · 15h ago
Fairfax exits IIFL Finance, sells stake for Rs 3,454 crore
The Economic Times · 18h ago
Mahanadi Coalfields raises Rs 2,295 crore from anchor investors ahead of IPO; LIC leads buying
ET Now · 1d ago
Mahanadi Coalfields IPO: LIC Takes A Quarter Of Rs 2,295 Crore Anchor Book
NDTV Profit · 1d ago
SBI MF leads institutional AUM; JioBlackRock has highest institutional share
Cafemutual · 1d ago
Goldman Sachs, Morgan Stanley, BNP Paribas buy IIFL Finance shares as Fairfax sells stake in Rs 3,500-cror
The Economic Times · 1d ago
Block Deals: Fairfax India sells Rs 3,488 crore worth of IIFL Finance shares; Rimco India, Nippon India,...
Moneycontrol.com · 1d ago
Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.
About Sectoral & Thematic funds
Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.
From the blog
98 equity funds with 20 years of NAVs: 89 beat Nifty's 9.7%
17 Oct 2026
98 regular-plan equity funds have NAVs from April 2006. Median return: 12.36% a year, against 9.68% for the Nifty 50 price index. Range: 7.4% to 17.2%.
Twenty years of equity funds: 98 with a full record
02 Oct 2026
98 equity funds have NAVs back to April 2006. Median returns by category since then run from 10.8% (large-cap) to 14.4% (small-cap), before survivorship.
Frequently asked questions
What is the NAV of Nippon India Pharma Fund?
As of 19 Nov 2026, the NAV of Nippon India Pharma Fund is ₹586.27 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.
What returns has Nippon India Pharma Fund delivered?
Nippon India Pharma Fund has returned +13.07% over 1 year, +16.77% per year over 3 years, +14.20% per year over 5 years and +17.61% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.
What is the expense ratio of Nippon India Pharma Fund?
Nippon India Pharma Fund charges an expense ratio of 1.85% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.
What are the top holdings of Nippon India Pharma Fund?
Nippon India Pharma Fund's largest holdings are Sun Pharmaceutical Industries Limited (11.6%), Divi's Laboratories Limited (6.7%), Cipla Limited (6.2%), Lupin Limited (6.2%) and Dr. Reddy's Laboratories Limited (6.1%). Holdings are disclosed monthly and change over time.
How risky is Nippon India Pharma Fund?
Nippon India Pharma Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 13.1% and its worst peak-to-trough fall in our sample was 47.4%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.
What does the Sharpe ratio of 0.78 mean?
The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Nippon India Pharma Fund's 0.78 means it has rewarded its volatility with excess return. Higher is better.
What is the benchmark of Nippon India Pharma Fund?
Nippon India Pharma Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.
Who manages Nippon India Pharma Fund?
Nippon India Pharma Fund is managed by Sailesh Raj Bhan at Nippon India.
When was Nippon India Pharma Fund launched, and what is its objective?
Nippon India Pharma Fund was launched on 05 Jun 2004. its stated objective is: The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.
How is Nippon India Pharma Fund taxed?
Nippon India Pharma Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.